RUSSO, Domenico
 Distribuzione geografica
Continente #
NA - Nord America 422
AS - Asia 98
EU - Europa 55
SA - Sud America 14
AF - Africa 9
Totale 598
Nazione #
US - Stati Uniti d'America 413
SG - Singapore 47
CN - Cina 33
IE - Irlanda 20
BR - Brasile 14
IT - Italia 10
BE - Belgio 9
CA - Canada 6
SN - Senegal 6
VN - Vietnam 6
IN - India 5
GB - Regno Unito 4
UA - Ucraina 3
CI - Costa d'Avorio 2
DE - Germania 2
RU - Federazione Russa 2
TR - Turchia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CH - Svizzera 1
FR - Francia 1
HN - Honduras 1
IQ - Iraq 1
JM - Giamaica 1
KE - Kenya 1
LB - Libano 1
LT - Lituania 1
MX - Messico 1
NL - Olanda 1
OM - Oman 1
UZ - Uzbekistan 1
Totale 598
Città #
Houston 174
Santa Clara 44
Dallas 39
Singapore 28
Chandler 26
Dublin 20
Chicago 16
Beijing 9
Brussels 9
Ashburn 8
Boardman 8
Andover 6
Cambridge 6
Civitanova Marche 6
Dakar 6
Falls Church 6
Lawrence 6
Los Angeles 5
Columbus 4
Des Moines 4
Dong Ket 4
The Dalles 4
Toronto 4
Wilmington 4
Nanjing 3
Shenyang 3
Zhengzhou 3
Abidjan 2
Brooklyn 2
Buffalo 2
Chennai 2
Frankfurt Am Main 2
Hanoi 2
Kochi 2
New York 2
Ottawa 2
Poplar 2
Redondo Beach 2
Redwood City 2
Alfenas 1
Ankara 1
Ann Arbor 1
Baghdad 1
Boston 1
Cabo Frio 1
City of London 1
Coelho Neto 1
Dubai 1
El Progreso 1
Elk Grove Village 1
Eusébio 1
Fazenda Nova 1
Franco da Rocha 1
Giresun 1
Hebei 1
Jacksonville 1
Jandira 1
Jiaxing 1
Kunming 1
Laranjal Paulista 1
London 1
Mandeville 1
Miami 1
Muscat 1
Naviraí 1
Norwalk 1
Oak Park 1
Orem 1
Osasco 1
Ouro Fino 1
Portmore 1
Porto Alegre 1
Presidente Dutra 1
Providence 1
Richmond 1
Saint Petersburg 1
San Jose 1
Seattle 1
Tianjin 1
Tijuana 1
Torre A Mare 1
Washington 1
Yingkou 1
Totale 523
Nome #
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 177
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 137
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP 92
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 78
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 66
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study 61
Totale 611
Categoria #
all - tutte 1.936
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.936


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 5 1 0 0 1 0 1 4
2021/202248 3 8 0 0 8 6 8 1 3 0 1 10
2022/202376 6 1 4 4 7 16 1 17 15 0 5 0
2023/202434 1 14 1 0 3 2 1 2 0 0 7 3
2024/2025147 1 25 9 14 35 22 1 4 8 13 12 3
2025/202698 16 6 37 13 26 0 0 0 0 0 0 0
Totale 611